Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important to establish standardized protocols to effectively detect and monitor MRD. At the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary, Wendy Stock, MD, of the University of Chicago Medical Centre, Chicago, IL, discusses the importance of MRD and highlights the impact of standardized techniques on accurate testing. Dr Stock draws attention to next-generation methodologies being the next step, if standard regulations can be drafted across the board.
Next-generation methodologies: the future for MRD monitoring in ALL?
